科研动态PubMed 摘要

基于GLP-1的疗法会重塑MASLD的流行病学吗?一个新出现的公共卫生视角。

PubMed 白名单日捞 · 2026-10-23

完整摘要 · 中文译文

代谢功能障碍相关脂肪性肝病(MASLD)是全球慢性肝病的主要原因,其驱动因素是肥胖和2型糖尿病的日益增多。胰高血糖素样肽-1受体激动剂(GLP-1RAs)使用的不断扩大提出了一个流行病学问题:针对这些代谢驱动因素的治疗能否重塑慢性肝病的未来负担?基于GLP-1的疗法可减轻体重并改善代谢功能障碍,对肝脂肪变性和疾病进展具有潜在意义。3期ESSENCE试验证明了司美格鲁肽在伴有中度至晚期纤维化的代谢功能障碍相关脂肪性肝炎(MASH)中的组织学获益,支持加速批准或有条件监管批准。然而,其对肝脏相关临床结局的影响仍未经证实。在本视角文章中,我们审视相关证据,并使用潜在影响分数将其转化为一个明确参数化的情景。结合已发表的关于合格性、相对风险、治疗持续性和有效性的估计值,以及5%、10%和20%的覆盖情景,该模型提示,在均衡状态下,在现患MASLD个体中,全球肝硬化发病率的相对降低约为0.3%至1.1%(20%覆盖率和中等持续性下的95%不确定性区间为0.6%至1.6%;最佳情况包络为4.6%)。这些估计值代表的是可检验的假设,而非已确立的临床效应。有效覆盖率,定义为覆盖率乘以持续性,是主要限制因素。我们识别出 将反驳这些预期的观察结果,并讨论其对预防、医疗保健系统及MASLD自然史的意义。人群获益将取决于持续治疗、可及性、可负担性和公平实施,同时还需确认组织学改善能够转化为更少的肝脏相关临床事件。

完整摘要 · 英文原文

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide, driven by increasing obesity and type 2 diabetes mellitus. The expanding use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) raises an epidemiological question: could therapies targeting these metabolic drivers reshape the future burden of chronic liver disease? GLP-1-based therapies reduce body weight and improve metabolic dysfunction, with potential implications for hepatic steatosis and disease progression. The phase 3 ESSENCE trial demonstrated histological benefits of semaglutide in metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis, supporting accelerated or conditional regulatory approvals. However, effects on liver-related clinical outcomes remain unproven. In this Perspective, we examine the evidence and translate it into an explicitly parameterized scenario using a potential impact fraction. Combining published estimates of eligibility, relative risk, treatment persistence, and effectiveness with coverage scenarios of 5%, 10%, and 20%, the model suggests relative reductions of approximately 0.3% to 1.1% in the global incidence of cirrhosis among individuals with prevalent MASLD, at equilibrium (95% uncertainty interval at 20% coverage and intermediate persistence, 0.6% to 1.6%; best-case envelope, 4.6%). These estimates represent testable hypotheses rather than established clinical effects. Effective coverage, defined as coverage multiplied by persistence, is the principal constraint. We identify observations that would refute these expectations and discuss implications for prevention, healthcare systems, and the natural history of MASLD. Population benefits will depend on sustained treatment, accessibility, affordability, and equitable implementation, alongside confirmation that histological improvements translate into fewer liver-related clinical events.

English
Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界